Roots Analysis has done a detailed study on “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/stem-cells-mark...

Key Market Insights
 Eminent representatives from different biopharmaceutical companies confirm the growing interest in stem cell therapy research, highlighting the prevalent and anticipated trends in ongoing R&D activities.
 More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy products for the treatment of a variety of disease indications.
 The pipeline features a variety of marketed / clinical therapies being evaluated across different stages targeting various types of stem cells; these products are designed for administration via diverse routes of administration.
 Stem cell therapies have demonstrated the applicability across over 25 unique therapeutic areas; cardiovascular, neurological, musculoskeletal and autoimmune / inflammatory disorders are presently the primary focus.
 Several organizations have extended financial support to aid research efforts in this domain; the current focus is on the evaluation of different stem cell types across multiple clinical conditions.
 In the last few years, over 540 clinical trials, evaluating various types of stem cell therapies in more than 52,000 patients, have been initiated; most of these trials are presently being conducted in centers across the US.
 As several therapy candidates progress towards regulatory approval, developers are exploring diverse commercialization strategies to be implemented across different stages of a product’s launch cycle.
 Owing to the rising demand for stem cell therapies, and challenges associated with manufacturing and scale up, industry players have demonstrated preferences to engage the services of contract service providers.
 More than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the specific unmet needs of therapy developers.
 Future growth of the market is likely to be driven by the success of different types of stem cell therapies, which are allogeneic and autologous in nature, as stakeholders continue to remain optimistic about proprietary products.
 The foreseen future market opportunity, based on the revenue generation potential of such therapies, is anticipated to be distributed across different therapeutic areas, end-users and key geographical regions.
 Products based on bone marrow derived adult stem cells are likely to continue to dominate the market in the mid-long term; adoption of therapies administered via novel routes of administration is likely to gradually rise.

For more information, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-mark...

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]